RecruitingInterventional

Comparison of Whole Body DWI to FDG PET Using PET/MRI

NCT ID: NCT06630845Sponsor: University of California, San FranciscoLast updated: 2026-04-03

Summary

This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.

Detailed description

PRIMARY OBJECTIVE: I. Correlation of DWI and FDG to detect disease. SECONDARY OBJECTIVE: I. Inter-reader variability of DWI interpretation by region. OUTLINE: Participants will be imaged at a single timepoint using whole body DWI concurrent with FDG PET/MRI within 60 days of receiving a non-FDG PET (either PET/CT or PET/MRI). There will be an optional PET/MRI performed within six months of the original study. Participants will be followed up through a medical records review for up to two years.

Arms & interventions

DrugFluorodeoxyglucose F18
Given IV as part of routine imaging
ProcedurePositron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)
Imaging procedure
ProcedureWhole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)
Imaging procedure done concurrently with PET/MRI
DeviceGeneral Electric (GE) SIGNA PET/MR
Imaging device

Outcome measures

Primary

Proportion of lesions characterized as positive
The overall proportion of lesions that will be characterized as positive on whole body (WB) diffusion weight imaging (DWI) and FDG PET.
Time frame: Up to 6 months

Secondary

Inter-reader variability of diffusion weight imaging (DWI) interpretation
Time frame: Up to 6 months

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No

Inclusion Criteria: 1. Age ≥ 18 years. 2. Non FDG PET imaging study scheduled to be performed within 60 days (before or after) of the research PET/MRI. 3. Ability to understand a written informed consent document, and the willingness to sign it. 4. Diagnosis of metastatic cancer. Exclusion Criteria: 1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation. 2. Individuals with contraindications to MRI. This will be determined through review of the UCSF MRI screening form by qualified site personnel

Study locations (1)

University of California, San Francisco

San Francisco, California, 94143

Recruiting

Brad Kline · Contact

Brad.Kline@ucsf.edu

· Contact

877-827-3222 cancertrials@ucsf.edu

Thomas Hope, MD · Principal Investigator